NEW YORK (GenomeWeb News) – Invitrogen said today that it has received US Food and Drug Administration premarket approval for its SPOT-Light HER2 CISH kit, which can be used to assess whether breast cancer patients should be treated with Genentech’s Herceptin (trastuzumab).
 
Invitrogen said that this is the first premarket approval that it has received from the FDA.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.